Set out below is the summarised financial information for Bioventus, adjusted for differences with Group accounting policies:
|
|
|
2017 |
|
2016 |
|
|
|
|
$ million |
|
$ million |
|
|
Summarised statement of comprehensive income |
|
|
|
|
|
|
Revenue |
|
301 |
|
282 |
|
|
Attributable profit/(loss) for the year |
|
1 |
|
(21) |
|
|
Group adjustments1 |
|
11 |
|
15 |
|
|
Total comprehensive profit/(loss) |
|
12 |
|
(6) |
|
|
Group share of profit/(loss) for the year at 49% |
|
6 |
|
(3) |
|
|
|
|
2017 |
|
2016 |
|
|
|
|
$ million |
|
$ million |
|
|
Summarised balance sheet |
|
|
|
|
|
|
Non-current assets |
|
332 |
|
364 |
|
|
Current assets |
|
122 |
|
105 |
|
|
Non-current liabilities |
|
(246) |
|
(258) |
|
|
Current liabilities |
|
(47) |
|
(53) |
|
|
Net assets |
|
161 |
|
158 |
|
|
Group’s share of net assets at 49% |
|
79 |
|
77 |
|
|
Group adjustments1 |
|
35 |
|
32 |
|
|
Group’s carrying amount of investment at 49% |
|
114 |
|
109 |
|
1 Group adjustments include an adjustment to align the useful life of intangible assets with Group policy.